A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
Marc Ychou(CEA Valduc), Jean‐Luc Raoul(EU Business School, Geneva), Jean‐Yves Douillard(Institut Génétique Nantes Atlantique), S. Gourgou-Bourgade(CEA Valduc), R. Bugat(Institut Claudius Regaud), Laurent Mineur(Institut Sainte Catherine), F. Viret(Centre Antoine Lacassagne), Y. Bécouarn(Institut Bergonié), Olivier Bouché(Centre Hospitalier Universitaire de Reims), E. Gamelin, Michel Ducreux(Institut Gustave Roussy), Thierry Conroy(Délégation Centre-Est), Julia Seitz(Hôpital de la Timone), Laurent Bedenne, A. Kramar(CEA Valduc)
Cited by 200
Abstract
Related Papers
No related papers found
Powered by citation graph analysis